Physician profile
Jeffrey E Prater
NPI 1659401461
$3,010.91
in general payments reported to CMS, 2019-2025
18 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.49 · 2022: $50.39 · 2023: $762 · 2024: $828 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.04 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $769.34 | 2023-2025 | Caplyta |
| Abbvie INC. | $559.35 | 2023-2025 | |
| Alkermes, INC. | $283.68 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $264.67 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $258.71 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $216.26 | 2024-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $180.69 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $118.01 | 2024-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $62.99 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $53.12 | 2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $47.14 | 2023-2025 | Auvelity |
| Corium, LLC | $46.87 | 2023-2025 | Azstarys |
| Noven Therapeutics, LLC | $35.52 | 2023-2024 | Secuado, Xelstrym |
| Indivior INC. | $34.53 | 2021-2022 | |
| Lilly USA, LLC | $29.58 | 2024 | Zepbound, Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $18.80 | 2022 | |
| Neuronetics, INC. | $18.24 | 2023 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $13.41 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Prater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.